Lineage Cell Therapeutics Inc. (AMEX: LCTX) is 52.84% higher on its value in year-to-date trading and has touched a low of $0.73 and a high of $3.13 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LCTX stock was last observed hovering at around $2.72 in the last trading session, with the day’s loss setting it -0.03% off its average median price target of $5.50 for the next 12 months. It is also 61.57% off the consensus price target high of $7.00 offered by 7 analysts, but current levels are 32.75% higher than the price target low of $4.00 for the same period.
Currently trading at $2.69, the stock is 11.25% and 11.70% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.87 million and changing -1.10% at the moment leaves the stock 62.70% off its SMA200. LCTX registered 249.35% gain for a year compared to 6-month gain of 124.17%. The firm has a 50-day simple moving average (SMA 50) of $2.3976 and a 200-day simple moving average (SMA200) of $1.8298.
The stock witnessed a 25.70% loss in the last 1 month and extending the period to 3 months gives it a 13.03%, and is 12.55% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.55% over the week and 7.19% over the month.
Lineage Cell Therapeutics Inc. (LCTX) has around 49 employees, a market worth around $434.76M and $1.80M in sales. Distance from 52-week low is 268.54% and -14.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-26.10%).
Lineage Cell Therapeutics Inc. (LCTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Lineage Cell Therapeutics Inc. (LCTX) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 2.10, where 1 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Lineage Cell Therapeutics Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $780k over the same period.The EPS is expected to shrink by -71.00% this year, but quarterly earnings will post 97.20% year-over-year. Quarterly sales are estimated to grow 51.80% in year-over-year returns.
Lineage Cell Therapeutics Inc. (LCTX) Top Institutional Holders
100 institutions hold shares in Lineage Cell Therapeutics Inc. (LCTX), with 7.48M shares held by insiders accounting for 4.63% while institutional investors hold 35.97% of the company’s shares. The shares outstanding are 150.57M, and float is at 142.42M with Short Float at 3.81%. Institutions hold 34.31% of the Float.
The top institutional shareholder in the company is Broadwood Capital, Inc. with over 34.01 million shares valued at $59.85 million. The investor’s holdings represent 21.04% of the LCTX Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 6.21 million shares valued at $10.93 million to account for 3.84% of the shares outstanding. The other top investors are Defender Capital, LLC which holds 4.95 million shares representing 3.06% and valued at over $11.63 million, while Prescott General Partners LLC holds 1.15% of the shares totaling 1.85 million with a market value of $3.26 million.
Lineage Cell Therapeutics Inc. (LCTX) Insider Activity
A total of 7 insider transactions have happened at Lineage Cell Therapeutics Inc. (LCTX) in the last six months, with sales accounting for 4 and purchases happening 3 times.